Navigation Links
COPD Patients Reveal Disease Progression Leads to Physical and Social Isolation and Increased Reliance on the Internet(1)
Date:11/17/2010

RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2010 /PRNewswire/ -- Patients with Chronic Obstructive Pulmonary Disease, or COPD, revealed that they perceive their disease as both a burden they must deal with and as a loss they have experienced,(1) according to recent in-home research conducted by GlaxoSmithKline.  Patients participating in the research characterized their sense of loss as a combination of factors including loss of energy, loss of control, loss of independence and loss of their old self.  They also suggested that COPD prevents them from living life to its fullest(1).  As the disease progresses, research participants report they've become increasingly limited in what they can do and more reliant on the internet as a source of important information on how to help manage their illness and as a means to interact with other people who can share in their experiences(1).

Patients with COPD can learn more on how to manage their disease by visiting www.COPD.com.  For the 12 million individuals diagnosed with COPD in the United States(2), www.COPD.com offers an easily accessible online destination to help inform them on their disease and its different stages and offers them things to consider that may help them live with COPD.  For caregivers, www.COPD.com offers information on how to care for a loved one with COPD.

About COPDAs the fourth leading cause of death in the United States(3), there are about 120,000 deaths attributed to COPD annually, more than breast cancer and diabetes combined(4). Every four minutes, someone dies from COPD in the United States(5). In addition to the 12 million individuals diagnosed with COPD, there are an additional 12 million people estimated with undiagnosed COPD(6).

COPD is a progressive, life-threatening lung disease that includes chronic bronchitis and emphysema. It is characte
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
2. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
3. Mortality Data Presented for Patients Treated with Effient® Who Underwent Isolated Coronary Artery Bypass Surgery
4. Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery
5. First-Line Use of Abilify Has More Than Doubled Over the Past Year for the Treatment of Newly-Diagnosed Patients in Bipolar Disorder
6. NIH-Funded Study Is First to Demonstrate Increased Long-Term Survival With Favorable Neurologic Function Among Patients Receiving CPR Using ACSI ResQPump™ and ResQPOD® CPR Devices
7. NT-proBNP Guided Therapy Keeps Heart Failure Patients out of the Hospital Through a Reduction in Cardiovascular Events
8. New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs
9. Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease
10. Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure With Mild Symptoms, Study Shows
11. Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today that on December 24, ... offering. The Company raised approximately $2.3 ... intends to use the net proceeds from the ...
(Date:12/24/2014)... and FARMINGTON, Conn. ... Inc. (NYSE MKT: PTN), a biopharmaceutical company developing ... diseases with significant unmet medical need and commercial ... a private placement of 2,050,000 shares of its ... 24,949,325 shares of its common stock.  Funds under ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... Kensey Nash Corporation (Nasdaq: KNSY ) ... Exemption (IDE) application to the U.S. Food and Drug ... unique biomaterials technology for treating articular cartilage defects of ... Cartilage Repair Device, which consists of a proprietary bi-phasic, ...
... MAP Pharmaceuticals, Inc. announced today that its initial Phase ... the potential treatment of children with asthma did not ... changes from baseline in nighttime and daytime composite symptom ... with placebo. AstraZeneca (NYSE: AZN ) ...
Cached Medicine Technology:Kensey Nash Announces IDE Submission for Cartilage Repair Device 2Kensey Nash Announces IDE Submission for Cartilage Repair Device 3Kensey Nash Announces IDE Submission for Cartilage Repair Device 4AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints 2
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is ... developing, producing and marketing of a series of induction ... their new series of induction brazing equipments . ... induction brazing refers to the joining of ... and heat. The manager says that there are fundamental ...
(Date:12/25/2014)... December 26, 2014 The report ... to 2023” focuses on the current treatment landscape, ... the colorectal cancer market. Stivarga is a drug ... or rectal cancer. Boehringer Ingelheim is developing nintedanib ... treatment of refractory CRC in the US, Europe, ...
(Date:12/25/2014)... 2014 Recently, Dylan Queen, a famous ... released its collection of discounted prom dresses, most of ... senior spokesman of the company, the promotion is valid ... is to expand the UK market. , The prom ... colors, lengths, and styles: A-line strapless, empire strapless chiffon, ...
(Date:12/25/2014)... FL (PRWEB) December 25, 2014 When head ... find themselves in a frenzy to get rid of it ... But families in Coral Gables now have the solution right ... second salon clinic location, Lice Troopers provides full spectrum head ... the Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut ...
(Date:12/25/2014)... Among early stage breast cancer patients who undergo chemotherapy ... will eventually develop leukemia as a result of their ... from a review of more than 20,000 breast cancer ... that the risk for developing treatment-related leukemia, though low, ... "The frequency of bone marrow cancers such as leukemia ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... sex hormones, testosterone in men and estrogen in women, ... of cartilage tissue. The study suggests hormone replacement in ... beneficial in treating late stages of human osteoarthritis (OA) ... study appear in the April issue of Arthritis ...
... some viral infections fatal and others much less severe ... part of the variability can be attributed to differences ... Katze, presenting at the Society for General Microbiology,s spring ... be a powerful tool to allow treatments to be ...
... this may be why they are less likely to ... (HealthDay News) -- Preconceived attitudes about breast-feeding may explain ... women to breast-feed their infants, a new study shows. ... 2006 were ever breast-fed, compared with 77 percent of ...
... ARBOR, Mich. While radiation therapy is common after ... even among women for whom it would have clear ... from researchers at the University of Michigan Comprehensive Cancer ... for breast cancer, assessing whether they had lumpectomy or ...
... An important gene that normally protects the body against ... on the specific mutation that damages it, according to ... University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and ... mutations in a gene called PTEN. People who inherit ...
... may affect decision-making and self-control , MONDAY, March 29 ... (CRP) are associated with problems in executive thinking skills, ... study. , CRP is considered an indicator of inflammation. ... scans and were given tests of verbal memory, word ...
Cached Medicine News:Health News:Hormone replacement in joint fluid has potential regenerative effect 2Health News:Personalizing medicine to prevent pandemics 2Health News:Black Women in U.S. Comfortable With Formula Feeding 2Health News:Radiation after mastectomy underused, U-M study finds 2Health News:Study shows that mutations in 1 gene cause many cancers 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: